BioXcel Therapeutics (BTAI) Inventory (2022 - 2026)

BioXcel Therapeutics' Inventory history runs 5 years deep, the most recent figure standing at $500000.0 for Q1 2026.

• On a quarterly basis, Inventory fell 22.12% year-over-year to $500000.0 in Q1 2026; TTM through Mar 2026 was $500000.0, a 22.12% decrease from a year earlier, with the FY2025 full-year figure at $722000.0, up 6.33% from the prior year.
• Inventory eased to $500000.0 in Q1 2026 per BTAI's latest filing, from $722000.0 in the prior quarter.
• Across five years, Inventory topped out at $2.7 million in Q2 2024 and bottomed at $459000.0 in Q3 2025.
• The 5-year median for Inventory is $1.4 million (2022), against an average of $1.4 million.
• Across the five-year window, Inventory soared 186.22% in 2023 and plunged 81.12% in 2025, its largest moves.
• Year by year, Inventory stood at $2.0 million in 2022, then advanced by 0.3% to $2.0 million in 2023, then slumped by 65.9% to $679000.0 in 2024, then rose by 6.33% to $722000.0 in 2025, then sank by 30.75% to $500000.0 in 2026.
• Per Business Quant, the three latest BTAI Inventory figures stand at $500000.0 (Q1 2026), $722000.0 (Q4 2025), and $459000.0 (Q3 2025).